Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. The company is headquartered in Bunkyo-Ku, Tokyo-To and currently employs 13,506 full-time employees. The firm operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The firm is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
Mr. Haruo Naito is the Chief Executive Officer of Eisai Co., Ltd., joining the firm since 1983.
What is the price performance of Eisai Co., Ltd. stock?
The current price of Eisai Co., Ltd. is $5.86, it has decreased 0.17% in the last trading day.
What are the primary business themes or industries for Eisai Co., Ltd.?
Eisai Co., Ltd. belongs to Pharmaceuticals industry and the sector is Health Care
What is Eisai Co., Ltd. market cap?
Eisai Co., Ltd.'s current market cap is $6.6B
Is Eisai Co., Ltd. a buy, sell, or hold?
According to wall street analysts, 18 analysts have made analyst ratings for Eisai Co., Ltd., including 3 strong buy, 5 buy, 9 hold, 1 sell, and 3 strong sell